Study on the Effect of PRKCB1 Modulating Inflammatory Factors and the Role for Developing Major Depressive Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Depressive disorder is known as being accompanied with the activation of immune system which could lead to a series of changes including the neuron apoptosis, synapses transmission inhibition and emotional symptoms. The activation of protein kinase C (PKC) can reverse the immune/inflammatory process and restore the neuroplasticity and neurotransmitters transmission. Based on our finding that patients with major depressive disorder (MDD) showed a significantly lower gene expression of PRKCB1, while the PKC activation mediated by PRKCB1, we hypothesize that PRKCB1 contribute to the development of MDD and treatment response by its specific expression in brain, regulating ERBB, Chemokine signaling pathways and PKC activation during the neuroinflammatory process. In the present study, we aim to evaluate and verify the regulation effect of PRKCB1 on the neuroimmune and inflammatory mechanism in depressive disorder by a serious of studies focus on PRKCB1 gene expression modulating process and different downstream biomarkers which associated with PRKCB1 effect, combined with the specified treatment (plus omega-3 poly unsaturated fat acids). This study may provide scientific evidences for using neuroinflammatory biomarkers to diagnose MDD, as well as personalized treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression

NCT04156425

Major Depressive Disorder

UNKNOWN NA

Neurotrophic Factors and Depression

NCT00812994

Depression

COMPLETED PHASE4

The Effects of Escitalopram on Cytokines

NCT01587326

Depression

UNKNOWN NA

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

NCT00183677

Depression

COMPLETED PHASE4

Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia

NCT05389046

Outpatients / Inpatients With Depression

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

(1）To find out the differences of expression of mRNA, lncRNA, miRNA and proteins of PRKCB1 between patients with depressive disorder and healthy subjects.

(2) Patients with depressive disorders will be randomized into two groups that they will be treated with escitalopram or escitalopram plus Omega-3 PUFAs. To observe the effects of Omega-3 PUFAs on PRKCB1 and related neuroimmune/neuroinflammatory pathway which may improve understanding the relationship between neuroinflammatory regulation and depressive disorder treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

group 1: escitalopram group 2: escitalopram + Omega-3 PUFAs

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

escitalopram

Patients will only be treated with escitalopram from the minimum dosage.

Group Type ACTIVE_COMPARATOR

escitalopram

Intervention Type DRUG

escitalopram 10-20 mg/d

escitalopram+ fish oil capsules

Patients will be treated with escitalopram from the minimum dosage and fish oil capsules according to direction for use.

Group Type EXPERIMENTAL

fish oil capsules

Intervention Type DIETARY_SUPPLEMENT

fish oil capsules(1000mg，EPA 180mg；DHA 120mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fish oil capsules

fish oil capsules(1000mg，EPA 180mg；DHA 120mg)

Intervention Type DIETARY_SUPPLEMENT

escitalopram

escitalopram 10-20 mg/d

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Drug-naive or medication free for no less than 4 weeks;
2. 18-60 years old, Han nationality;
3. Junior high school diploma or above;
4. Meeting with the criteria of major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-TR;
5. Scored 17 or higher on the Hamilton's Depression Scale with 17 items (HAMD-17) and scored 2 or higher for the 2nd item (depressive mood);
6. Written informed consent has been obtained.

Exclusion Criteria

1. Concurring psychotic disorders;
2. Woman who is pregnant or breast feeding or is planning to get pregnant;
3. Scores 3 or higher on item 3 (suicidal) of HAMD-17;
4. serious allergy or disease of immune system;
5. had anti-inflammatory drug or immunosuppressant in the past 1 month;
6. serious medical or surgical illness or history;
7. had MECT in the past 1 month.

Eligibility Criteria for healthy volunteers:

1. match the patient group in age, gender, education and handedness;
2. no history of psychiatric disorders or debilitating general medical disorders.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes